Zadaxin thymosin alpha I immunomodulator regulatory update

SCLN received Canadian Patent No. 2,157,479 covering the use of Zadaxin to treat hepatitis C virus (HCV) infection. The company expects to begin by year end U.S. and European Phase III testing of Zada...